Pennsylvania v. Tap Pharmaceutical Products, Inc.

415 F. Supp. 2d 516, 2005 U.S. Dist. LEXIS 19967, 2005 WL 2242913
CourtDistrict Court, E.D. Pennsylvania
DecidedSeptember 9, 2005
Docket2:05-cv-03604
StatusPublished
Cited by19 cases

This text of 415 F. Supp. 2d 516 (Pennsylvania v. Tap Pharmaceutical Products, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pennsylvania v. Tap Pharmaceutical Products, Inc., 415 F. Supp. 2d 516, 2005 U.S. Dist. LEXIS 19967, 2005 WL 2242913 (E.D. Pa. 2005).

Opinion

OPINION

SANCHEZ, District Judge.

The Commonwealth of Pennsylvania is suing thirty-eight pharmaceutical companies, alleging price-setting fraud. The pharmaceutical companies would like to remove the case to federal court. Because I find the lawsuit sounds' solely in state law, I will grant the Commonwealth’s motion to remand.

In their unified notice of removal, the Defendants assert the Commonwealth’s lawsuit arises under federal law because recovery is predicated on the meaning of “average wholesale price,” a term, which until recently, governed reimbursement for certain prescription drugs under Medicare. The Commonwealth argues its pleading raises purely state-law causes of action not dependent on the meaning of “average wholesale price” as the term was used in the Medicare statute. Alternatively, the Commonwealth argues even if federal-question jurisdiction exists, the Defendants failed to remove this case in a timely manner. The Defendants also ask this Court to stay its consideration of the motion to remand because they have sought transfer of this lawsuit to multi-district litigation underway in the District of Massachusetts, a request I will deny.

*519 BACKGROUND

In March, 2004, the Commonwealth of Pennsylvania filed a lawsuit against thirteen pharmaceutical companies in Commonwealth Court of Pennsylvania, alleging violations of state law. The Commonwealth Court dismissed the complaint without prejudice on February 1, 2005 based upon the pharmaceutical companies’ preliminary objections. Undeterred, on March 10, 2005, the Commonwealth, through its Attorney General, filed a Corrected Amended Civil Action Complaint (“Amended Complaint”) that names thirty-eight pharmaceutical companies as defendants. Many of the thirty-eight entities identified in the caption are subsidiaries or affiliates of one another, so the allegations in the Amended Complaint are essentially directed against fourteen pharmaceutical defendants. Specifically, each Defendant faces a count for unjust enrichment, misrepresentation/fraud, and violations of the Commonwealth’s Unfair Trade Practices and Consumer Protection Law (“UTPCPL”). There is also a count against the Defendants collectively for civil conspiracy, and the Commonwealth invokes its ability to proceed parens patriae (as “parent of the state”) for those citizens who were adversely affected by Defendants’ allegedly wrongful conduct.

The Commonwealth complains the pharmaceutical companies have engaged in an unlawful sales and marketing scheme to artificially inflate the average wholesale price (“AWP”) of drugs since 1991. Accordingly, the Amended Complaint prays for compensatory and punitive damages, as well as injunctive relief.

The AWP for a prescription drug is a number generated by the pharmaceutical company that manufactures the drug. AWP is the standard for reimbursement under many of the Commonwealth’s social welfare programs. 1 Simply stated, the Commonwealth reimburses beneficiaries of various social welfare programs, such as Medicaid, for their purchase of prescription drugs. The price at which these beneficiaries purchase and receive reimbursement is based upon AWP data promulgated by the Defendants. Until recently, Medicare reimbursed health-care providers in the Commonwealth up to eighty percent of the AWP for prescriberdispensed drugs used to treat Medicare beneficiaries.

A substantial portion of the Amended Complaint is devoted to the recovery the Commonwealth seeks for itself, and the Defendants do not assert the meaning of AWP as it pertains to reimbursement at the state level implicates a federal issue. The Defendants also do not claim the Commonwealth’s parens patriae claim to recover inflated copayments or direct purchases made by its citizens gives rise to federal-question jurisdiction. The only claim the Defendants assert confers federal-question jurisdiction is the Commonwealth’s parens patriae claim to recover Medicare copayments based on allegedly inflated AWPs. The Defendants argue the Commonwealth must prove a discrepancy between reported AWPs and the meaning *520 of AWP as it was once used in the Medicare statute.

When Medicare based reimbursement for prescriber-dispensed drugs on AWP, there were no federal regulations for calculating a drug’s “average wholesale price.” Additionally, neither Medicare nor the Department of Health and Human Services established a process whereby AWPs could be accurately ascertained for federal Medicare purposes. Medicare beneficiaries in the Commonwealth who received prescriber-dispensed drugs paid the remaining twenty-percent of the drug’s cost in the form of a copayment. These copayments were based on the AWP figures generated by the pharmaceutical manufacturers.

Pharmaceutical companies do not report AWP information directly to Medicare or the Commonwealth. Instead, drug manufacturers report AWP data to independent publishers of pharmaceutical-trade compendia designed to disseminate this information. The independent publishers do not verify the accuracy of AWP data. The Commonwealth claims the Defendants used the lack of government and private oversight of AWP data to their advantage by creating a “spread” between the price at which they sold prescription drugs to providers (e.g., physicians, pharmacies, and pharmacy benefit managers) and the AWP figure reported to the independent publishers. Defendants allegedly made their respective drug products more attractive to these providers because they could profit from reimbursements the Commonwealth and federal government paid on the spread. According to the Commonwealth, Medicare beneficiaries in Pennsylvania paid more for prescriber-dispensed prescription drugs as a result of inflated AWPs. To recover these overpayments, the Commonwealth’s Attorney General is proceeding parens patriae against the Defendants. Defendants assert the definition of AWP raises a substantial question of federal law.

On July 13, 2005, Defendants filed a unified notice of removal with this Court pursuant to 28 U.S.C. § 1441(b), which permits cases to be removed to federal court if the plaintiffs cause of action arises under federal law. Two days later, Defendants submitted a Notice of Related Action (otherwise known as a “Tag-Along Notice”) to the Joint Panel for Multi-district Litigation (“JPML”) requesting this case, as well as ten others brought by Attorneys General from Alabama, Illinois, Kentucky, Minnesota, New York, and Wisconsin against many of the same defendants here, be transferred to MDL 1456, In re Pharmaceutical Industry Average Wholesale Price Litigation, underway in the District of Massachusetts. The JPML issued a conditional transfer order as a matter of course on August 9, 2005, to which the Commonwealth filed a notice of opposition. As a result, the conditional transfer order is stayed until further order from the JPML pursuant to Rule 7.4(c). DISCUSSION

Defendants’ motion to stay is a request to have the jurisdictional issue decided in MDL 1456. They argue it would be an inefficient use of judicial resources for this Court to consider the motion to remand.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hulley Enterprises Ltd. v. Russian Federation
211 F. Supp. 3d 269 (District of Columbia, 2016)
New Mexico ex rel. Balderas v. Preferred Care, Inc.
158 F. Supp. 3d 1226 (D. New Mexico, 2015)
Oregon ex rel. Kroger v. Johnson & Johnson
832 F. Supp. 2d 1250 (D. Oregon, 2011)
Kentucky ex rel. Conway v. Purdue Pharma, L.P.
821 F. Supp. 2d 591 (S.D. New York, 2011)
In Re Oxycontin Antitrust Litigation
821 F. Supp. 2d 591 (S.D. New York, 2011)
Pennsylvania v. Eli Lilly & Company, Inc.
511 F. Supp. 2d 576 (E.D. Pennsylvania, 2007)
Disher v. Citigroup Global Markets, Inc.
487 F. Supp. 2d 1009 (S.D. Illinois, 2007)
Hilbert v. Aeroquip, Inc.
486 F. Supp. 2d 135 (D. Massachusetts, 2007)
Dudley v. Putnam Investment Funds
472 F. Supp. 2d 1102 (S.D. Illinois, 2007)
Hawaii v. Abbott Laboratories, Inc.
469 F. Supp. 2d 842 (D. Hawaii, 2006)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
457 F. Supp. 2d 77 (D. Massachusetts, 2006)
Burns v. Prudential Securities, Inc.
450 F. Supp. 2d 808 (N.D. Ohio, 2006)
Betts v. Eli Lilly and Co.
435 F. Supp. 2d 1180 (S.D. Alabama, 2006)
People v. Abbott Laboratories
431 F. Supp. 2d 98 (D. Massachusetts, 2006)
In Re Pharm. Industry Average Wholesale Price
431 F. Supp. 2d 98 (D. Massachusetts, 2006)
Commonwealth Ex Rel. Pappert v. TAP Pharmaceutical Products, Inc.
885 A.2d 1127 (Commonwealth Court of Pennsylvania, 2005)
State of Wisconsin v. Abbott Laboratories
390 F. Supp. 2d 815 (W.D. Wisconsin, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
415 F. Supp. 2d 516, 2005 U.S. Dist. LEXIS 19967, 2005 WL 2242913, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pennsylvania-v-tap-pharmaceutical-products-inc-paed-2005.